ANGPTL3-FLD (anti-ANGPTL3-FLD) nano antibody and application thereof
By designing anti-ANGPTL3-FLD nanoantibodies, combining the Fc segment to form VHH-Fc fusion protein, the problem of short half-life and high immunogenicity in the body is solved, and the efficient recognition and stable existence of ANGPTL3 is achieved, with potential treatment of tumors , application of kidney disease and metabolism-related diseases.
Patent Information
- Application Number
- CN202411319062.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-21
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-09-21
AI Technical Summary
Existing antibodies have short half-life in vivo, high immunogenicity, and are unable to effectively recognize specific epitopes, making them difficult to exist stably in the body for a long time, and lack effective treatment strategies for diseases such as coronary heart disease and diabetes.
An anti-ANGPTL3-FLD nanoantibody was designed to use the variable region of VHH antibody of camels, bind to the Fc segment, and form a VHH-Fc fusion protein, enhancing its half-life and affinity in vivo, improving its immunogenicity and stability. sex.
The high affinity, low immunogenicity and good thermal stability of anti-ANGPTL3-FLD nanobody was achieved, which prolonged the half-life in the body, enhanced the recognition ability of ANGPTL3, and had potential treatment of tumors, renal diseases and metabolism. Application of related diseases.
Smart Images

Figure BDA0005053173800000071 
Figure HDA0005053173810000011 
Figure HDA0005053173810000012
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology and antibody engineering pharmaceuticals, and specifically relates to an anti-ANGPTL3-FLD nano antibody and an application thereof. Background Art
[0002] Nanobodies (VHH) are single-domain antibodies composed of the variable region (VHH) of heavy chain antibodies naturally present in the serum of camelids (such as camels and alpacas). The uniqueness of this antibody is that it contains only a heavy chain variable region and no light chain, which makes them smaller in molecular weight and higher in tissue penetration than traditional antibodies (S. Muyldermans. "Nanobodies: natural single-domain antibodies." Annual Review of Biochemistry (2013).; Wang Landong, Feng Dongxiao, Zhang Shumin. Research Progress of Nanobodies [J]. Biotechnology Communications, 2016, 27 (03): 453-458.). Nanobodies have significant advantages in the fields of cancer treatment (Zhou Huihui, Chen Qu, Yang Xiaomei, et al. Research progress of nanoantibodies in cancer treatment [J]. Life Science, 2022, 34(04): 468-476.), infectious disease prevention, diagnosis and treatment (Mei Yaxian, Wang Yue, Luo Wenxin. Application of nanoantibodies in the prevention, diagnosis and treatment of infectious diseases [J]. Chinese Journal of Biotechnology, 2020, 40(10): 24-34.) and immunoassay (Mei Yaxian, Wang Yue, Luo Wenxin. Application of nanoantibodies in the prevention, diagnosis and treatment of infectious diseases [J]. Chinese Journal of Biotechnology, 2020, 40(10): 24-34.) due to their small molecular weight, high stability and low immunogenicity. In addition, they have high expression levels, good water solubility, strong stability, easy production and storage, and are suitable for development as engineered antibodies.
[0003] Nanobody fusion protein is a fusion of nanobody with other functional proteins or fragments through genetic engineering technology to enhance its function and application range. Since the molecular weight of nanobody itself is only about 15kD, it will be filtered through the glomerular barrier and quickly cleared during metabolism in the body, and because it does not have an Fc segment, it cannot produce cytotoxic effects such as ADCC / CDC like traditional antibodies. Therefore, VHH antibody is often fused with Fc segment to increase the half-life of VHH-Fc fusion protein in the body to prolong the protein action time, and ADCC and CDC activities are added depending on the specific situation.
[0004] Angiopoietin-like protein 3 (ANGPTL3) is a secretory glycoprotein whose structure includes an amino-terminal coiled-coil domain (CCD), a secretory signal peptide, a short connecting peptide, and a carboxyl-terminal globular fibrinogen-like domain (FLD). Studies have shown that increased levels of ANGPTL3 are associated with the occurrence of a variety of diseases, including coronary heart disease, diabetes, hepatocellular carcinoma, breast cancer, etc. In particular, in patients with coronary heart disease, increased plasma ANGPTL-3 levels are positively correlated with the severity of the disease (Gao Kaile. Plasma angiopoietin-like protein 3 levels in patients with coronary heart disease and its clinical significance [J]. Guangxi Medicine, 2021, 43(1): 31-34, 51.). In addition, ANGPTL3 is closely related to the invasion and metastasis of hepatocellular carcinoma, and its expression intensity in tumor tissue is significantly higher than that in peritumoral tissue (Song Qitong, Shan Yunfeng, Zhou Mengtao, et al. Study on the expression of angiopoietin-like protein 3 and its relationship with invasion and growth of hepatocellular carcinoma [J]. Chinese Journal of Hepatobiliary Surgery, 2006, 12(7): 450-452.). As an important secretory protein, ANGPTL3 plays an important role in the pathogenesis of many diseases such as lipid metabolism regulation, cardiovascular disease, diabetes and its complications. Therefore, in-depth research on the function of ANGPTL3 and its role in disease is of great significance for the development of new treatment strategies. Summary of the invention
[0005] Based on the advantages of nano-antibodies such as the ability to recognize specific epitopes, low immunogenicity, good permeability and easy modification, the present invention constructs an anti-ANGPTL3-FLD nano-antibody with high affinity, and the present invention is completed based on this.
[0006] In a first aspect, the present invention provides an anti-ANGPTL3-FLD nanobody, wherein the heavy chain variable region of the nanobody is VHH128, VHH252 or VHH376, wherein the amino acid sequence of VHH128 is shown in SEQ ID NO.1; the amino acid sequence of VHH252 is shown in SEQ ID NO.2; and the amino acid sequence of VHH376 is shown in SEQ ID NO.3.
[0007] In a second aspect, the present invention provides a nucleic acid molecule encoding the anti-ANGPTL3-FLD nanobody as described in the first aspect of the present invention.
[0008] In a third aspect, the present invention provides an antibody conjugate, wherein the antibody conjugate comprises the anti-ANGPTL3-FLD nanobody described in the first aspect of the present invention.
[0009] In a fourth aspect, the present invention provides a composition comprising the anti-ANGPTL3-FLD nanobody or a pharmaceutically acceptable carrier thereof according to the first aspect of the present invention.
[0010] In a fifth aspect, the present invention provides an anti-ANGPTL3-FLD nanobody as described in the first aspect of the present invention, or the antibody conjugate as described in the third aspect of the present invention, or the composition as described in the fourth aspect of the present invention for the preparation of a drug for preventing or treating tumors, kidney diseases or metabolic-related diseases.
[0011] In a sixth aspect, the present invention provides an application in a reagent for detecting ANGPTL3-FLD protein, wherein the reagent contains the anti-ANGPTL3-FLD nanobody as described in the first aspect of the present invention.
[0012] In a seventh aspect, the present invention provides a kit for detecting ANGPTL3-FLD protein, the kit comprising instructions and a detection reagent, and the detection reagent is the reagent described in the sixth aspect of the present invention.
[0013] Beneficial Effects
[0014] The anti-ANGPTL3-FLD nanobody and its fusion protein prepared by the present invention have good thermal stability and colloidal stability, and have similar particle sizes; the prepared nanobody can recognize specific epitopes, has low immunogenicity, good permeability and is easy to transform; the prepared nanobody fusion protein has a purity of up to 100% and has good affinity with the antigen. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 SDS-PAGE results, concentration and total amount of recombinant expressed antigen.
[0016] Figure 2 Results of serological titer testing of alpacas before and after immunization.
[0017] Figure 3 Agarose gel electrophoresis results of total RNA from PBMCs from triple and quadruple immunizations. M: DNA marker; 1: RNA from triple immunizations; 2: RNA from quadruple immunizations.
[0018] Figure 4 Agarose gel electrophoresis results of the first-round amplification products of nested PCR.
[0019] Figure 5 Agarose gel electrophoresis results of the second-round amplification products of nested PCR.
[0020] Figure 6 The results of plate culture were determined for transformants in the library.
[0021] Figure 7 Agarose gel electrophoresis results of colony PCR.
[0022] Figure 8 Library construction and diversity sequencing amino acid alignment sequence results.
[0023] Fig. 9 Construction of a phylogenetic tree of library diversity sequencing analysis results.
[0024] Fig.10 Affinity panning results of the recombinant antigen hANGPTL3-FLD-His.
[0025] Fig.11 Phage supernatant ELISA test results.
[0026] Fig.12 SDS-PAGE results of recombinantly expressed VHH-His.
[0027] Fig.13 ELISA test results of recombinantly expressed VHH-His.
[0028] Fig.14 SPR detection results of recombinantly expressed candidate VHH-His.
[0029] Fig.15 Schematic diagram of the construction of nanoantibody fusion protein VHH-Fc.
[0030] Fig.16 SDS-PAGE results of nanobody fusion protein VHH-Fc.
[0031] Fig.17 SEC-HPLC results of nanobody fusion protein VHH-Fc.
[0032] Fig.18 UNcle instrument detection results of nanobody fusion protein VHH-Fc.
[0033] Fig.19 SPR affinity test results of nanobody fusion protein VHH-Fc. DETAILED DESCRIPTION
[0034] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in the embodiments described below can be combined with each other as long as they do not conflict with each other.
[0035] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.
[0036] Example 1 Recombinant Expression of Antigen
[0037] 1.1 Test methods
[0038] Taking into account the differences in half-life and structure of different forms of antigens, two antigens were designed and synthesized, namely hANGPTL3-FLD-Fc and hANGPTL3-FLD-His. The former is mainly used for animal immunization, and the latter is mainly used for antibody screening. The pTT5 vector was used to connect the above gene fragments and then transferred into cells for expression. The purified protein was verified by SDS-PAGE for subsequent experiments.
[0039] 1.2 Test results
[0040] After recombinant expression and purification, 12 mg of hANGPTL3-FLD-Fc at a concentration of 10 mg / ml and 20.4 mg of hANGPTL3-FLD-His at a concentration of 17 mg / ml were obtained. The molecular weights of the two antigens in the reduced and non-reduced states on SDS-PAGE were consistent with expectations and the protein purity was good (e.g. Figure 1 shown).
[0041] Example 2 Alpaca Immunization
[0042] 2.1 Test materials
[0043] Experimental animals: Adult healthy alpacas (Alpaca);
[0044] Recombinant expressed antigen: hANGPTL3-FLD-Fc.
[0045] 2.2 Test methods
[0046] Multiple rounds of alpaca immunization were carried out, and negative serum before immunization was collected as a control and serum after the second, third, and fourth immunizations was used to evaluate the immunization effect. The specific process is as follows:
[0047] Day 0: 10 mL of blood was collected as a negative serum control, and hANGPTL3-FLD-Fc antigen was mixed with CFA and injected;
[0048] On day 21, hANGPTL3-FLD-Fc antigen was mixed with IFA and injected;
[0049] On day 28, blood was collected for titer testing;
[0050] On day 42, hANGPTL3-FLD-Fc antigen was mixed with IFA and injected;
[0051] On day 49, blood was collected for titer testing and peripheral blood lymphocytes were isolated;
[0052] On day 63, hANGPTL3-FLD-Fc antigen was mixed with IFA and injected;
[0053] On day 70, blood was collected for titer testing and peripheral blood lymphocytes were isolated.
[0054] 2.3ELISA method to detect immunological titer
[0055] The recombinant antigen hANGPTL3-FLD-His was diluted and coated overnight;
[0056] Discard the coating solution, wash, add skim milk, and seal;
[0057] Wash, add diluted serum, and incubate;
[0058] Wash, add diluted Goat anti-Alpaca IgG (H+L) HRP, and incubate;
[0059] Wash the plate, add TMB colorimetric solution for color development, incubate, add stop solution, and detect the optical density.
[0060] 2.4 Test results
[0061] The retained pre-immune serum was used as a negative control and the second, third, and fourth immunization sera were graded diluted and coated with the recombinant expressed antigen hANGPTL3-FLD-His antigen overnight for ELISA detection. OD450>0.2 after the serum was diluted from 1:32K to 1:64K was considered a positive result. The results showed that the OD450 of the three-immunity serum was 0.2646 after 1:32K dilution, the OD450 of the four-immunity serum was 0.6134 after 1:32K dilution, and the OD450 of the four-immunity serum was 0.3548 after 1:64K dilution, indicating that the three-immunity and four-immunity sera reached a positive serological titer and can be used for subsequent experiments (such as Figure 2 shown).
[0062] Example 3 RNA extraction and reverse transcription products
[0063] 3.1 RNA extraction and reverse transcription products
[0064] Peripheral blood was collected after triple and quadruple immunizations, and peripheral blood mononuclear cells (PBMCs) were separated to extract total RNA, and the purity was verified by electrophoresis and reverse transcribed. Subsequently, the cDNA of the reverse transcription products of triple and quadruple immunizations were mixed in equal proportions and diluted, PCR amplified, electrophoresed, and gel-recovered. The VHH fragment of about 750 bp was amplified, electrophoresed, and gel-recovered and purified to obtain the target VHH fragment.
[0065] The vector pComb3XSS and the target fragment VHH were digested with SfiI, recovered, ligated, and plasmids were constructed for electroporation transformation, resuscitation, and the resuscitation products were collected.
[0066] After gradient dilution, the number of transformants in the library was determined by spreading on the plate. The rest was centrifuged and the supernatant was discarded, then resuspended and spread. The number of transformants in the library was inferred by the number of clones on the plate. The clones were picked to determine the insertion rate and sequenced. The sequencing primer was pComb3XSS-F. The sequencing results were analyzed by Sequencher Scanner v1.0 and DNASTAR software to obtain the amino acid alignment sequence and evolutionary tree of the library diversity.
[0067] 3.2 Test results
[0068] After collecting peripheral blood and isolating PBMC to extract RNA, agarose gel electrophoresis was performed, and the results showed that the RNA bands were clear and of good purity (such as Figure 3 The above RNA was reverse transcribed, and the cDNA of the triple and quadruple reverse transcription products were mixed in equal proportions and diluted, and a PCR amplification was performed. The amplified products were subjected to agarose gel electrophoresis. The results showed that there were obvious bands around 750 bp and 1000 bp, respectively, for VHH and VH fragments (such as Figure 4 The VHH fragment of about 750 bp was recovered by gel electrophoresis for the second round of amplification. The agarose gel electrophoresis results showed that the VHH band was bright and clear (as shown in Figure 5 After gel recovery, the target VHH fragment was purified using a DNA product purification kit.
[0069] Example 4 Phage Library Packaging
[0070] 4.1 Test methods
[0071] The bacterial library was inoculated into 2YT+A+G medium, with an initial OD600 of 0.1-0.2, and cultured until OD600 was above 0.8;
[0072] Add helper phage M13KO7 and mix well;
[0073] After centrifugation, discard the supernatant and resuspend in culture medium overnight;
[0074] Centrifuge, collect the supernatant, discard the precipitate, centrifuge again, collect the supernatant;
[0075] Add PEG8000 / NaCl, mix well, and place on ice;
[0076] After centrifugation, discard the supernatant, resuspend the precipitate, and add PEG8000 / NaCl for secondary precipitation;
[0077] After centrifugation, discard the supernatant, resuspend the precipitate, add glycerol to a final concentration of 50%, mix well, and aliquot for storage;
[0078] Take the library phage for gradient dilution, pipette and mix with TG1 bacterial solution, spread on Amp resistance plate, culture, and calculate the phage library titer by the number of clones on the titer plate.
[0079] 4.2 Test results
[0080] Take the electro-conversion recovery product and dilute it to 10 -3 and 10 -4 Spread on a plate, and count 240 clones on a library transformant assay plate the next day (e.g. Figure 6 As shown in Figure 2, the library capacity can be deduced to be 2.40×10 9 (240×10 4 ×10).
[0081] 48 clones were selected from the library transformant titration plate for colony PCR and then agarose gel electrophoresis. The results showed that the vector fragments of all clones were clearly visible and the insertion rate was 100% (e.g. Figure 7 shown).
[0082] After sequencing and analyzing the diversity of the above 48 clones, the amino acid alignment sequence results and phylogenetic tree showed that the library had good diversity (e.g. Figure 8 and Fig. 9 As shown), the next step of screening can be carried out.
[0083] Example 5 Phage Library Affinity Panning
[0084] 5.1 Affinity panning assay method
[0085] Dilute the recombinant antigen hANGPTL3-FLD-His to a final concentration of 5 μg / mL and add it to the enzyme-labeled wells. Coat 8 wells for each target molecule overnight.
[0086] Discard the coating solution, wash, add 3% OVA-PBS blocking solution, and block;
[0087] Wash, add phage library, and incubate;
[0088] Aspirate unbound phage and wash;
[0089] Add an elution buffer, incubate, elute the specifically bound phage, transfer the elution buffer to a centrifuge tube, and neutralize with a buffer;
[0090] The gradient dilution was performed, the titer was determined, the panning recovery rate was calculated, and the remaining eluates were mixed, amplified and purified, and used for the next round of affinity panning. The panning conditions were changed. The panning conditions for each round are shown in Table 1.
[0091] Table 1. Panning conditions
[0092]
[0093] 5.2 Amplification of the library after panning
[0094] The panning eluate was mixed with the E. coli TG1 culture in the early logarithmic growth period, glucose was added, cultured, M13K07 phage and 4 ul Amp+ were added, culture medium was added, and cultured;
[0095] Aliquot the culture, centrifuge, resuspend the pellet, and culture;
[0096] After centrifugation, the supernatant was aspirated, PEG-NaCl was added, and mixed;
[0097] After centrifugation, discard the supernatant, resuspend the precipitate, add PEG / NaCl, and mix well;
[0098] After centrifugation, discard the supernatant and suspend the precipitate in PBS, which is the amplification product. Determine the titer for selection or analysis.
[0099] 5.3 Test results
[0100] In fact, two rounds of affinity panning were carried out (such as Fig.10 shown):
[0101] In the first round, 5 μg / ml of antigen was used for coating, and the library input was 2×10 11 cfu, the recovery amount is 9.68×10 5 cfu, the recovery rate was 4.84×10 -6 ;
[0102] In the second round, 2 μg / ml antigen was used for coating, and the library input was 1x10 11 cfu, the recovery amount is 1.62×10 7 cfu, the recovery rate was 1.62×10 -4 , the enrichment degree is 33.47.
[0103] Example 6 Identification and analysis of specific phage clones
[0104] 6.1 Phagemid rescue
[0105] Select clones, inoculate, and culture;
[0106] Take the above culture, add M13K07 phage, and culture;
[0107] Add 2×YT-AK and culture;
[0108] The supernatant was collected by centrifugation and used for monoclonal ELISA identification.
[0109] 6.2 Identification of positive phage clones
[0110] A. Test Methods
[0111] Dilute the recombinant antigen hANGPTL3-FLD-His to a final concentration of 2 μg / mL, add it to the enzyme-labeled wells, and coat overnight;
[0112] Discard the coating solution, wash, add skim milk, and seal;
[0113] Wash, add phage culture supernatant and skim milk, and incubate;
[0114] After washing, horseradish peroxidase-labeled anti-M13 antibody was added;
[0115] Wash the plate, add TMB color developing solution, develop color, add stop solution, and measure the optical density at 450 nm.
[0116] B. Test Results
[0117] 480 clones were selected from the second round of titer determination plates, and the phage supernatant was taken for ELISA determination after expansion culture. The results showed that a total of 432 positive clones were screened (such as Fig.11 ), 396 monoclonal clones were successfully sequenced, including 92 full-length specific sequences and 53 CDR3 specific sequences.
[0118] 6.3 Sequencing and analysis of positive phage clones
[0119] The positive phage clones obtained from the above screening were sent for sequencing, and the sequencing results were analyzed using Sequencher Scannerv1.0 and DNASTAR software to obtain the library diversity amino acid alignment sequence and evolutionary tree.
[0120] The full-length specific sequences were further summarized, with special attention paid to the CDR3 specific sequences. After sequence specificity analysis using DNASTAR software, the sequences were selected to construct VHH-His proteins in combination with phage ELISA data. After recombinant expression, ELISA and SPR methods were used to detect their affinity to the antigen to determine the candidate sequences.
[0121] 6.4 Nanobody candidate sequence screening
[0122] Based on the sequence specificity and phage supernatant ELISA test data, 11 His-tagged nanoantibodies VHH-His were selected and constructed. Except for antibody No. 6, which showed abnormally low expression, the other 10 antibodies were expressed normally and had good purity (e.g. Fig.12 ELISA and SPR methods were used to detect the affinity of VHH-His and human ANGPTL3 molecules to obtain three high-affinity candidate antibodies (as shown in Fig.13 and Fig.14 The candidate sequences are as follows:
[0123] VHH128
[0124] QLQLVESGGGLVQPGGSLRLSCAASGFTLDYYTIGWFRQAPGKEREGISCINSRGSGTNYA
[0125] DSVAGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADVADIGGPTCPLYSDFLDYWGQ
[0126] GTQVTVSS
[0127] VHH252
[0128] EVQVVESGGGLVQPGGSLRLSCAASGFTLDNYYIVWLRQAPGKEREGVSCISRDGGTTKY
[0129] ADSATGRFTISSRDNAKDTVYLQMNSLKPEDTGVYYCAAVFSTLQYICFITVRNADYWGQ
[0130] GTQVIVSS
[0131] VHH376
[0132] QLQLVESGGGLVQPGGSLRLSCTASGFTLDYYAIAWFRQAPGKEREGISCISSRGGSTNYA
[0133] DSVRGRFTISRDNAKNMVYLQMNRLKPEDTAIYYCAADVGALSGCVFGPGYEYDYWGQ
[0134] GTQVTVSS
[0135] Example 7 Construction and characterization of nanobody fusion protein
[0136] 7.1 Construction of Nanoantibody Fusion Protein
[0137] The human IgG1-Fc sequence was connected to the C-terminus of the candidate antibody sequence. The fusion protein sequence was connected to the pcDNA3.4 vector after gene synthesis. HEK293F cells were used for protein expression. The cell supernatant was centrifuged and purified by ultrafiltration using a Protein A affinity chromatography column to obtain the target protein.
[0138] The human IgG1-Fc sequence was connected to the C-terminus of the above three candidate antibody sequences respectively. After gene synthesis, the restriction sites XbaI and EcoRV were used to connect with the vector pcDNA3.4. The constructed plasmid was used for subsequent transfection (such as Fig.15 7.2 SDS-PAGE detection of antibody molecular weight
[0139] Tris-glycine gel was prepared and electrophoresis was performed under reducing and non-reducing conditions. The voltage was set to 80 V for concentration and 120 V for separation. After the electrophoresis, the gel was taken out and stained with Coomassie Brilliant Blue, then rinsed with destaining solution overnight, and the image was taken to determine the molecular weight based on the band position.
[0140] After the above plasmids were transfected into HEK293F cells for protein expression, they were purified by Protein A column affinity chromatography and verified by SDS-PAGE. The results showed that the three nanobody fusion proteins VHH-Fc showed clear protein bands in both reduced and non-reduced states, with molecular weights in line with expectations and good purity (such as Fig.16 shown).
[0141] 7.3 SEC-HPLC to detect the purity of antibodies
[0142] After diluting the purified protein, inject it into the chromatographic column and detect it under ultraviolet irradiation to determine the purity of the antibody.
[0143] The protein purity of the above three nano antibody fusion proteins VHH-Fc was tested by SEC-HPLC, and the results showed that the protein purity was very good and reached 100% (such as Fig.17 shown).
[0144] 7.4 DLS detection of antibody stability, particle size and dispersion coefficient
[0145] Use a protein stability analyzer to obtain the polydispersity, particle size, and particle size distribution of the sample, explore the unfolding and aggregation characteristics of the protein during the heating process, and determine the Tm and Tagg values to reveal the thermal stability and colloidal stability of the antibody.
[0146] The three nano-antibody fusion proteins VHH-Fc were further characterized using the UNcle instrument. The results showed that the Tm value of 128-Fc was 61.62°C, the Tagg value was 67.02°C, the particle size was 7.46nm, and the PDI was 0.226; the Tm value of 252-Fc was 61.09°C, the Tagg value was 79.59°C, the particle size was 8.06nm, and the PDI was 0.053; the Tm value of 376-Fc was 60.41°C, the Tagg value was 60.49°C, the particle size was 7.46nm, and the PDI was 0.141 (as shown in Figure 2). Fig.18 shown).
[0147] The above results show that the three nanoantibody fusion proteins VHH-Fc have good thermal stability and colloidal stability, and have similar particle sizes, but the polydispersity coefficients are quite different, suggesting that the existence forms of different proteins in the solution may be different. 7.5 SPR detection of antibody-antigen affinity
[0148] Surface plasmon resonance (SPR) analysis was performed. Human IgG capture antibodies were pre-immobilized on a CM5 chip. The antibodies were captured on the chip by adjusting the capture time. The antigen hANGPTL3 was then passed over the chip for binding and dissociation. The affinity was calculated using the binding and dissociation parameters generated by the system.
[0149] The SPR experimental method was used to detect the affinity of the above three nanoantibody fusion proteins VHH-Fc and the antigen hANGPTL3-His using a Biacore T200 instrument. The results showed that the KD value of 128-Fc was 1.59E-10M, the KD value of 252-Fc was 3.82E-10M, and the KD value of 376-Fc was 1.65E-10M, all of which showed good and similar affinities (such as Fig.19 shown).
Claims
1. An anti-ANGPTL3-FLD nanobody, wherein the heavy chain variable region of the nanobody is VHH128, VHH252 or VHH376, in, The amino acid sequence of VHH128 is shown in SEQ ID NO.1; the amino acid sequence of VHH252 is shown in SEQ ID NO.2; and the amino acid sequence of VHH376 is shown in SEQ ID NO.
3.
2. A nucleic acid molecule encoding the anti-ANGPTL3-FLD nanobody according to claim 1.
3. An antibody conjugate, comprising the anti-ANGPTL3-FLD nanobody according to claim 1.
4. A composition comprising the anti-ANGPTL3-FLD nanobody according to claim 1 or a pharmaceutically acceptable carrier thereof.
5. Use of the anti-ANGPTL3-FLD nanobody according to claim 1, the antibody conjugate according to claim 3, or the composition according to claim 4 in the preparation of a drug for preventing or treating tumors, kidney diseases or metabolic-related diseases.
6. Use in a reagent for detecting ANGPTL3-FLD protein, wherein the reagent contains the anti-ANGPTL3-FLD nanobody according to claim 1.
7. A kit for detecting ANGPTL3-FLD protein, the kit comprising instructions and a detection reagent, wherein the detection reagent is the reagent according to claim 6.
Citation Information
Patent Citations
Long-acting bifunctional protein as well as preparation method and application thereof
CN113831413A
Anti-CSFV E2 protein nano antibody, fusion protein, and preparation method and application of anti-CSFV E2 protein nano antibody and fusion protein
CN114957454A
Anti-human angiopoietin 3 nano antibody and application thereof
CN116284377A
